Immunotherapy as a targeted therapy in non-small cell lung cancer

In the present era, non-small cell lung cancer (NSCLC) represents the principal cause of death for cancer worldwide (about 80%), showing a high incidence (about 1,350,000 new diagnosis each year) and mortality (about 1,180,000 deaths each year) (1).